Kinzey Capital Management: Pharma Lifts Bayer's 2026 Outlook

What happened: Bayer raised its full-year earnings guidance after third-quarter pharmaceutical sales climbed 8%, with impairments and special charges leaving the quarter at a net loss and a Roundup settlement awaiting court approval. Key numbers: Q3 pharma sales $5.2 billion, up 8%. Shares rose more than 5%. Why it matters: Kinzey Capital Management attributes most of the upgrade to pharmaceuticals rather than cost cuts, and the firm says headline earnings and underlying cash generation warrant separate reading where one-off legal charges shape the reported result.

Bayer raised its full-year earnings guidance after third-quarter pharmaceutical sales climbed 8%, with impairments and special charges leaving the quarter at a net loss and a Roundup settlement awaiting court approval.

Kinzey Capital Management attributes most of the upgrade to pharmaceuticals rather than cost cuts, and the firm says headline earnings and underlying cash generation warrant separate reading where one-off legal charges shape the reported result.